Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) (Xolair)
Sponsor: University of California, Davis
Listed as NCT00367016, this PHASE4 trial focuses on Allergic Rhinitis and Asthma and remains completed. Sponsored by University of California, Davis, it has been updated 10 times since 2004, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Feb 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, Davis
For direct contact, visit the study record on ClinicalTrials.gov .